FibroGen's competitors

FibroGen's competitors include Minerva Neurosciences, AstraZeneca, Bristol-Myers Squibb and Novartis
Add company...
FibroGen
FibroGen is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics to treat serious unmet medical needs.
Minerva Neurosciences
Minerva Neurosciences is a clinical-stage biopharmaceutical company.
AstraZeneca
AstraZeneca, a global pharmaceutical company, discovers, develops, manufactures and markets prescription medicines.
Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
Novartis
Novartis provides healthcare solutions that address the evolving needs of patients and societies.
Founding Date
Founding Date
1993
Founding Date
2007
Founding Date
1999
Founding Date
1887
Founding Date
1996
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Subsidiary
Tags
Locations
Locations
San Francisco, US HQ
Locations
Waltham, US HQ
Locations
Cambridge, GB HQ
Sydney, AU
Brussels, BE
Winnipeg, CA
Mississauga, CA
Montreal, CA
Windsor, CA
see more
Locations
New York, US HQ
Bi, DE
Lawrence Township, US
Devens, US
Hopewell, US
Mulhuddart, IE
Zug, CH
see more
Locations
Basel, CH HQ
Beijing, CN
Wehr, DE
Tokyo, JP
New York, US
East Hanover, US
Employees
Employees
364
Employees
11
Employees
59,700
Employees
23,700 5% decrease
Employees
121,597
Valuation ($)
Valuation ($)
3.4 b
Valuation ($)
277.4 m
Valuation ($)
87.4 b
Valuation ($)
83.7 b
Valuation ($)
N/A
Facebook likes
Facebook likes
68
Facebook likes
N/A
Facebook likes
25.6 k
Facebook likes
120.2 k
Facebook likes
304.3 k
Twitter followers
Twitter followers
N/A
Twitter followers
N/A
Twitter followers
141.3 k
Twitter followers
120.8 k
Twitter followers
234.4 k

Financial

Revenue (est.)
Revenue (est.)
$125.7m (FY, 2017)
Revenue (est.)
N/A
Revenue (est.)
$21.3b (FY, 2016)
Revenue (est.)
$19.4b (FY, 2016)
Revenue (est.)
$48.5b (FY, 2016)
Cost of goods
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
$4.1b (FY, 2016)
Cost of goods
$4.9b (FY, 2016)
Cost of goods
$17.5b (FY, 2016)
Gross profit
Gross profit
N/A
Gross profit
N/A
Gross profit
$17.2b (FY, 2016)
Gross profit
$14.5b (FY, 2016)
Gross profit
$31b (FY, 2016)
Net income
Net income
($126.2m) (FY, 2017)
Net income
($31.5m) (FY, 2017)
Net income
$3.4b (FY, 2016)
Net income
$4.5b (FY, 2016)
Net income
$6.7b (FY, 2016)

Operating

Phase I Trials Products
Phase I Trials Products
N/A
Phase I Trials Products
1 (FY, 2016)
Phase I Trials Products
41 (FY, 2016)
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase II Trials Products
Phase II Trials Products
1 (FY, 2016)
Phase II Trials Products
3 (FY, 2016)
Phase II Trials Products
36 (FY, 2016)
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase III Trials Products
Phase III Trials Products
1 (FY, 2016)
Phase III Trials Products
N/A
Phase III Trials Products
27 (FY, 2016)
Phase III Trials Products
8 (Y, 2016)
Phase III Trials Products
29 (Y, 2016)
Projects in R&D Pipeline
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
N/A
Projects in R&D Pipeline
132 (FY, 2016)
Projects in R&D Pipeline
44 (Y, 2016)
Projects in R&D Pipeline
N/A
For sources of this data, please see the company profileDownload Excel

View company profiles